Why taking patient history never ends

Publication
Article
Optometry Times JournalOptometry Times October 2019
Volume 11
Issue 10

pediatric patient
Ben Casella

I don’t like to read. I never did, and, still today, I’m more of a “wait until the movie comes out” kind of guy. I’m very fortunate in that our kids take after their mother in this regard (among others). 

I am a moderate myope, and I’m pretty sure that my contact lenses are a little stronger than they should be. This would account for my low degree of accommodative esophoria which becomes more manifest later in the day.  

You are thinking, “Cycloplege yourself and find out your true degree of myopia!” 

No. I’m not doing that, and you can’t make me. I’m not bothered by my vision. I just plain don’t like to read.

With this in mind, I saw a new patient the other day who reminded me why the patient history “never ends.” A seven-year-old presented with his mother and three siblings as new patients. The other three siblings checked out fine. The seven-year-old had no overt complaints. I asked him and his mother if there were problems with the board at school or with reading or concerns from the teacher. No one had any bad news to offer.

Previously by Dr. Casella: Make sure patients know follow-up visits may be covered 

Then his mother added, “Well, he doesn’t like reading, anyway.” I asked the child why not, and he said he just didn’t like reading.

You can tell where this is headed. As it turned out, the child was a mild latent hyperope of around 1.50 D OU. Best corrected visual acuity was 20/20 OU, and I wasn’t able to elicit frank phoria. Ocular health was unremarkable, and I released him with a prescription for as-needed wear at near. 

I asked the child’s mother to call me about a week after the glasses were dispensed, and she reported that she had noticed no changes in behavior but that he seemed to enjoy wearing them. That is one of those non-verbal cues that I pay attention to because it means I likely did something right. 

I hope I have helped create a bookworm out of this child-or that he at least doesn’t continue an aversion to reading. Had his mother not casually mentioned that little factoid about reading, I may well have accepted the report of no concerns at near and moved on. Looking back, however, I see the reality implied within that response: How can there be concerns with reading if one doesn’t read to begin with?

How do you pry for such lurking variables within a patient’s (especially a younger patient’s) visual well-being? I’m eager to know; drop me a line. In the meantime, I’ll be waiting for the movie to come out.

Read more editorials here 

Recent Videos
Optometrists reflect on their residency experiences and provide advice to current residents.
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
Bonnie An Henderson, MD, the cofounder and program director of EnVision Summit
What was the biggest innovation in eye care in 2024?
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
© 2024 MJH Life Sciences

All rights reserved.